Co-Authors
This is a "connection" page, showing publications co-authored by Michael Joyner and Arturo Casadevall.
Connection Strength
6.135
-
The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. mBio. 2021 03 02; 12(2).
Score: 0.932
-
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021 03 18; 384(11):1015-1027.
Score: 0.924
-
Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020 09 01; 130(9):4791-4797.
Score: 0.901
-
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat Commun. 2021 08 11; 12(1):4864.
Score: 0.240
-
COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses. 2021 08 11; 13(8).
Score: 0.240
-
Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy. Clin Infect Dis. 2021 08 02; 73(3):e540-e542.
Score: 0.240
-
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne). 2021; 8:684151.
Score: 0.237
-
Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife. 2021 06 04; 10.
Score: 0.237
-
Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021 08; 61(8):2503-2511.
Score: 0.237
-
SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. J Clin Invest. 2021 04 01; 131(7).
Score: 0.234
-
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 05; 96(5):1262-1275.
Score: 0.232
-
Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. Clin Microbiol Newsl. 2021 Feb 15; 43(4):23-32.
Score: 0.232
-
Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. N Engl J Med. 2021 01 14; 384(2):189.
Score: 0.230
-
The Assessment of Convalescent Plasma Efficacy against COVID-19. Med (N Y). 2020 Dec 18; 1(1):66-77.
Score: 0.230
-
SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. J Clin Invest. 2020 10 01; 130(10):5112-5114.
Score: 0.226
-
A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals. JAMA. 2020 08 04; 324(5):455-457.
Score: 0.224
-
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020 09; 95(9):1888-1897.
Score: 0.223
-
COVID-19 convalescent plasma: Interim recommendations from the AABB. Transfusion. 2021 04; 61(4):1313-1323.
Score: 0.058
-
Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 06 01; 130(6):2757-2765.
Score: 0.055